Contact Us


¡¡Eradication of Cancer Cells via Regeneration

1. Killing of Cancer and Transformed Cells in vitro
2. Selective Killing of Cancer Cells Co-Cultured with Normal Cells
3. Promoting Growth of Normal Cells in vitro
4. Differential Metabolism of MEBO Regenerative Nutrients in Cancer and Normal Cells
5. Killing of Cancer Cells in Tumor Tissue in vitro
6. Suppression of Ascites Tumor Growth in Animal Tumor Models
7. Eradication of Skin Cancer in Patients
8. Eradication of Leukemia in Patients
9. Regeneration of internal organs of cancer patients
10. Ongoing Clinical Studies of End-Stage Cancer Patients

10. Ongoing Clinical Studies of End-Stage Cancer Patients

Formally commenced on Janurary 25, 2008 in China, MEBO initiated a large-scale clinical studies of end-stage cancer patients who had failed all medical interventions and given up upon further medical treatment (as certified by patients¡¯ oncologists).  About 300 end-stage cancer patients, exhibiting a variety of different cancer types (including lung, liver, gastrointestinal (esophagus, stomach, colon, rectal cancer), pancreas, breast, prostate, uterus/cervix, ovarian, thymus, neuroblastoma) were enrolled and provided with MEBO regenerative nutrients.  Preliminary results are extremely encouraging: most patients (~80% overall 1-year survival rate) not only survived but also improved significantly in all detectable indexes including the body weight, reduction in tumor size, elimination of leukemia cells (in patients with relapsed leukemia), and improvement in mobility and vitality. 

For example, a 58 year-old female patient was diagnosed with right lung cancer that had metastasized to the bone, and was treated with chemotherapy for 3 courses without surgical operation. The treatment modality did not improve her condition and she still coughed up blood (haemoptysis) and had a persistent pain in her right ribs.  She subsequently gave up upon such treatment and started taking the MEBO regenerative nutrients in February 2008.  Four months after her overall condition improved: haemoptysis disappeared; rib pains alleviated; and appetite, complexion and vitality improved (Figure 10.10.1a).  The tumor in her right lung regressed from a size of 30x43 mm to 27x29 mm.

Remarkably and surprisingly, after 4 months on the MEBO regenerative nutrients the patient who had suffered from hair loss due to chemotherapy started grow thick, lush and lustrous black hair (Figure 10.10.1b-c) that appeared to be even healthier than a typical woman of her age.  The texture of her skin also improved, becoming suppler and smoother.  Interestingly, her breasts seemed to become firmer and vaginal discharge that had disappeared 7-8 years ago reappeared. 

Currently these patients have voluntarily elected to continue getting nutritional support from MEBO and their monthly reports are gathered by MEBO for further analysis. 

The results obtained from MEBO¡¯s 1-year clinical studies, although preliminary, are very encouraging. They demonstrate that by using the MEBO regenerative nutrients as nutritional support, cancer patients, even if at a late or end stage, can still benefit from this unique modality in the absence of conventional medical intervention or after failure of all medical interventions.  The patients not only survived but also enjoy better quality of life.  In some cases, such as relapsed acute leukemia and gastrointestinal cancer, the patients have had complete remission and remarkably improved vital indexes. Continuous taking of the MEBO nutrients also seemed to have certain rejuvenating effects on the patients who manifested certain degree of tissue/organ regeneration during the course, such as growing healthier-, younger-looking skin and hair. 

These preliminary results obtained by MEBO in its cellular, tissue and human studies should shed new light on cancer research, prevention and treatment.  Since the 1950¡¯s, despite the enormous amounts of funding targeted for cancer research by the governments and private entities throughout the world, it is yet far away from claiming victory in the ongoing war against cancer.  It has been predicted that one in two men and one in three women are likely to die of cancer.  World Fact Book, Central Intelligence Agency, Office of Public Affairs, Washington, D.C., July 2006.  Thus, it can be estimated that, if anti-cancer agents with long-term curative effects are not found soon, particularly for advanced metastatic cancers, about 2.7 billion people would die of cancer, considering there are about 6.5 billion people in the world today.  In the United States, and in the rest of the world, people are still looking for the first ¡°Magic Bullet¡± that will consistently destroy in different patients both primary and metastatic cancers regardless of their tissue of origin while exhibiting minimal toxicity to the human host.  Pederson (2007), supra. 

Against this grim background, MEBO beckons as a bright beacon for the world.  Built upon solid scientific and clinical foundations and with superior safety profiles, the MEBO approach of utilizing its dual-functional regenerative nutrients and technologies offers enormous hope for humanity as a whole, and globally it will have a profound impact on the currently overburdened health care systems and overstressed economies in both developed and developing countries. 

Core Science & Technology of MEBO
Exploration of Fundamental Mechanisms of Adult Human Body Regeneration
Eradication of Cancer Cells via Regeneration

About us | Contact us | Link | Version | Sitemap | Glossary
Copyright© 2009 mebo.Com .All Rights Reserved